Abstract
Background The role of glomerular endothelial cell fenestrations in renal filtration function and development fenestral ultrastructural changes in disease contributing to loss of function is poorly described.
Methods We determined glomerular ultrastructural changes with comprehensive characterisation of fenestral findings and also functional changes including measurement of glomerular ultrafiltration coefficient in diabetic mice and humans. We further evaluated Eps homology domain protein 3 (Ehd3) as a potential regulator of glomerular endothelial cell fenestrations.
Results This study identified loss of GEnC fenestration density which was associated with decreased glomerular ultrafiltration coefficient and GFR in diabetic nephropathy. We also identified increased GEnC fenestration width, an ultrastructural change that may develop to maintain filtration surface area. GEnC fenestration width was negatively associated with glomerular ultrafiltration coefficient and GFR considered to be a result of the development of diaphragms in widening fenestrations providing resistance to filtration. The increased presence of diaphragmed fenestrations in diabetes was supported by increased PV1 expression. We further identified decreased glomerular Ehd3 expression in diabetes and demonstrated its association with GEnC fenestration measurements suggesting its role in regulating fenestrations. We also demonstrated its positive associations with filtration function suggesting loss of glomerular Ehd3 expression in disease may contribute to declining glomerular filtration function through aberrant GEnC fenestration regulation.
Conclusions This is the first study to demonstrate the critical role of glomerular endothelial cell fenestrations in renal filtration function and identify a potential key regulator that may serve as a therapeutic target to retore filtration function in disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N.C.F and this research were funded by a Wellcome Trust Clinical postdoctoral fellowship award (104507/Z/14/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Bristol and Southmead Hospital research ethics committee H0102/45
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Please contact the first author regarding data availability
